ESH CLL 2022 – Federico Pea

Federico Pea draws attention to the most relevant differences between first-generation and next-generation BTK inhibitors observed at the pharmacokinetic level in terms of antitumor activity, how differences in kinase selectivity affect the tolerability of these drugs, which patient groups appear suitable for first-generation or next-generation BTK inhibitor therapy and outlines, from a pharmacologists point of view, what clinicians should keep in mind when treating CLL patients with BTK inhibitors.

Here is the full ESH CLL 2022 report.